Rituximab Therapy for Steroid-Refractory Chronic Graft Versus Host Disease

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Dana-Farber Cancer Institute
Study ID
NCT00136396
Phase
PHASE1/PHASE2
Status
Completed

Conditions

  • Graft vs Host Disease

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Rituximab — DRUG
    Given once weekly for 4 weeks followed by a 4 week observation therapy.

Study Details

The purpose of this study is to determine if rituximab is a safe and effective therapy for steroid-refractory chronic graft versus host disease (GVHD).

Key Dates

Start date
Jan 31, 2004
Status verified
Jun 2013
Primary completion
Nov 30, 2006
Completion
Nov 30, 2010

Study Design

Enrollment
30 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

To determine the safety and efficacy of up to three four week courses of rituximab in steroid-refractory chronic GVHD [ Time Frame: 2 years ]

Locations (2)

FacilityCityStateZIPSite coordinators
Brigham and Women's HospitalBostonMassachusetts02115-
Dana-Farber Cancer InstituteBostonMassachusetts02115-

Find similar trials in Boston, MA

By research site
Brigham and Women's Hospital· Boston, MADana-Farber Cancer Institute· Boston, MA

Related Studies